R1 Rcm Inc. RCM
We take great care to ensure that the data presented and summarized in this overview for R1 RCM Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RCM
View all-
New Mountain Vantage Advisers, L.L.C. New York, NY94.4MShares$1.35 Billion40.72% of portfolio
-
Black Rock Inc. New York, NY16.5MShares$236 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.3MShares$204 Million0.0% of portfolio
-
Fil LTD Hamilton, D013.9MShares$199 Million0.19% of portfolio
-
Glazer Capital, LLC New York, NY9.58MShares$137 Million7.91% of portfolio
-
Melqart Asset Management (Uk) LTD London, X04.8MShares$68.7 Million6.64% of portfolio
-
State Street Corp Boston, MA4.78MShares$68.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.16MShares$59.5 Million0.03% of portfolio
-
Coliseum Capital Management, LLC Rowayton, CT3.5MShares$50.2 Million4.9% of portfolio
-
Highland Capital Management Fund Advisors, L.P. Dallas, TX3.21MShares$45.9 Million5.37% of portfolio
Latest Institutional Activity in RCM
Top Purchases
Top Sells
About RCM
R1 RCM Inc. provides technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. It offers end-to-end revenue cycle management (RCM) services, which address the spectrum of revenue cycle challenges faced by healthcare providers. The company also provides modular services, including physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. The company was founded in 2003 and is headquartered in Murray, Utah.
Insider Transactions at RCM
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 19
2024
|
John B Henneman Iii |
SELL
Sale (or disposition) back to the issuer
|
Direct |
87,765
-100.0%
|
$1,228,710
$14.3 P/Share
|
Nov 19
2024
|
David M Dill |
SELL
Sale (or disposition) back to the issuer
|
Direct |
49,522
-100.0%
|
$693,308
$14.3 P/Share
|
Nov 19
2024
|
Kyle Hicok Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
356,975
-100.0%
|
$4,997,650
$14.3 P/Share
|
Nov 19
2024
|
Kyle Hicok Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
306,621
+46.21%
|
-
|
Nov 19
2024
|
Bradford Kyle Armbrester |
SELL
Sale (or disposition) back to the issuer
|
Direct |
26,975
-100.0%
|
$377,650
$14.3 P/Share
|
Nov 19
2024
|
John M. Sparby President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
640,191
-100.0%
|
$8,962,674
$14.3 P/Share
|
Nov 19
2024
|
John M. Sparby President |
BUY
Grant, award, or other acquisition
|
Direct |
332,323
+34.17%
|
-
|
Nov 19
2024
|
Joseph Gerard Flanagan |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,485,379
-100.0%
|
$48,795,306
$14.3 P/Share
|
Nov 19
2024
|
Joseph Gerard Flanagan |
BUY
Grant, award, or other acquisition
|
Direct |
98,238
+2.74%
|
-
|
Nov 19
2024
|
Scanlan Agnes Bundy |
SELL
Sale (or disposition) back to the issuer
|
Direct |
33,014
-100.0%
|
$462,196
$14.3 P/Share
|
Nov 19
2024
|
Jennifer D. Williams Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
423,479
-100.0%
|
$5,928,706
$14.3 P/Share
|
Nov 19
2024
|
Jennifer D. Williams Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
355,006
+45.6%
|
-
|
Nov 19
2024
|
Lee Rivas Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,604,819
-100.0%
|
$22,467,466
$14.3 P/Share
|
Nov 19
2024
|
Lee Rivas Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,247,137
+43.73%
|
-
|
Nov 19
2024
|
Michael C. Feiner |
SELL
Sale (or disposition) back to the issuer
|
Direct |
61,041
-100.0%
|
$854,574
$14.3 P/Share
|
Nov 19
2024
|
Pamela L. Spikner Principal Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
33,522
-100.0%
|
$469,308
$14.3 P/Share
|
Nov 19
2024
|
Pamela L. Spikner Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,767
+16.8%
|
-
|
Nov 19
2024
|
Jeremy Delinsky |
SELL
Sale (or disposition) back to the issuer
|
Direct |
26,975
-100.0%
|
$377,650
$14.3 P/Share
|
Nov 19
2024
|
Anthony R Tersigni |
SELL
Sale (or disposition) back to the issuer
|
Direct |
75,989
-85.37%
|
$1,063,846
$14.3 P/Share
|
Nov 19
2024
|
Jill D. Smith |
SELL
Sale (or disposition) back to the issuer
|
Direct |
62,453
-100.0%
|
$874,342
$14.3 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 2.94M shares |
---|---|
Exercise of in-the-money or at-the-money derivatives securities | 40.5M shares |
Sale (or disposition) back to the issuer | 7.05M shares |
---|---|
Payment of exercise price or tax liability | 119K shares |
Other acquisition or disposition | 155M shares |
Open market or private sale | 30.6M shares |